Effect of long term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia

Dorota Górecka, Katarzyna Gorzelak, Paweł Śliwiński, Miroslaw Tobiasz, Jan Zielinski

Abstract
Background – To date only two controlled studies have been published on the effects of domiciliary oxygen treatment on survival in patients with chronic obstructive pulmonary disease (COPD) with advanced respiratory failure. The survival in such patients despite oxygen treatment remains poor. The prescription of long term oxygen therapy (LTOT) in less severe disease remains controversial. The aim of this study was to evaluate the rationale for prescribing oxygen to patients with COPD with moderate hypoxaemia.

Methods – One hundred and thirty five patients with COPD, with PaO2 7.4–8.7 kPa (56–65 mmHg) and advanced airflow limitation (mean (SD) forced expiratory volume in one second (FEV1) 0.83 (0.28) l), were randomly allocated to a control (n = 67) and LTOT (n = 68) group. The patients were followed every three months for at least three years or until death.

Results – The cumulative survival rate was 88% at one year, 77% at two years, and 66% at three years. No significant differences were found in survival rates between patients treated with LTOT and controls, nor did longer oxygen use (over 15 hours per day) improve survival. Younger age, better spirometric values, and higher body mass index predicted better survival.

Conclusions – Domiciliary oxygen treatment does not prolong survival in patients with COPD with moderate hypoxaemia. Airway limitation seems to determine survival in this group of patients.

Thorax 1997;52:674–679

Keywords: chronic obstructive pulmonary disease, moderate hypoxaemia, long term oxygen therapy, survival.

Long term oxygen therapy (LTOT) is generally accepted as a therapeutic measure in patients with chronic respiratory failure. Although LTOT is prescribed in various lung diseases leading to chronic hypoxia, its beneficial effects have only been evaluated in patients with chronic obstructive pulmonary disease (COPD) and severe hypoxaemia (PaO2 <8.0 kPa (60 mmHg)) in whom a substantial improvement in survival has been shown. Patients with COPD are usually given LTOT in the advanced stage of the disease and long term survival in such patients, despite oxygen treatment, remains poor. It has been suggested that LTOT should be prescribed earlier in the natural history of the disease, and in some countries oxygen is also prescribed to patients with moderate hypoxaemia (PaO2 7.4–8.7 kPa (56–65 mmHg)). However, no controlled studies have been reported to show that the implementation of LTOT in this group of patients also prolongs life. The aim of our study was therefore to evaluate the rationale of prescribing oxygen in patients with COPD with moderate hypoxaemia.

Methods
One hundred and thirty five consecutive patients with COPD referred to nine regional LTOT centres in Poland with moderate hypoxaemia (PaO2 7.4–8.7 kPa (56–65 mmHg)) entered the study in the years 1987–92 and were followed up to the end of 1994. The organisation of domiciliary oxygen therapy in Poland and qualification procedures have been described previously.

We included patients with COPD as a single diagnosis, aged between 40 and 80 years, with airway limitation defined by FEV1/VC post bronchodilator of <70%. Patients with serious disease of organs other than the lungs that might influence survival were excluded from the study. Baseline studies included a complete history, physical examination, and basic laboratory tests. Spirometric measurements and blood gas tensions were measured twice, at least three weeks apart, in all patients, along with a chest radiograph and ECG before entering the study. Patients were randomly allocated to receive either conventional treatment (controls) or conventional treatment plus oxygen (LTOT). Randomisation schedules were developed centrally. Treatment assignments were computer generated by random numbers, with an equal number of patients in the control and treatment groups. Usual treatment consisted of bronchodilators (theophylline, β2 agonists, and anticholinergic drugs). Antibiotics, diuretics, and corticosteroids were prescribed at the discretion of the physician. Prolonged use of corticosteroids was defined...
Table 1: Mean (SD) clinical characteristics of 135 patients with COPD at entry to the study

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total (n = 135)</th>
<th>Control group (n = 67)</th>
<th>LTOT group (n = 68)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61.2 (8.5)</td>
<td>62.4 (8.2)</td>
<td>60.1 (8.8)</td>
</tr>
<tr>
<td>MP</td>
<td>103/32</td>
<td>52/15</td>
<td>51/17</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.6 (6.0)</td>
<td>23.3 (4.0)</td>
<td>23.8 (5.1)</td>
</tr>
<tr>
<td>PaO₂ (kPa/mmHg)</td>
<td>8.0 (0.4)/60.4 (2.8)</td>
<td>8.2 (0.4)/61.3 (2.7)</td>
<td>7.9 (0.4)/59.5 (2.7)*</td>
</tr>
<tr>
<td>PaCO₂ (kPa/mmHg)</td>
<td>5.9 (0.9)/44.1 (6.7)</td>
<td>5.7 (0.9)/42.8 (6.6)</td>
<td>6.0 (0.9)/45.3 (6.7) *</td>
</tr>
<tr>
<td>VC (l)</td>
<td>1.95 (0.59)</td>
<td>1.98 (0.54)</td>
<td>1.94 (0.64)</td>
</tr>
<tr>
<td>VC (% pred)</td>
<td>48.9 (11.9)</td>
<td>50.0 (11.6)</td>
<td>47.7 (12.2)</td>
</tr>
<tr>
<td>FEV₁ (% pred)</td>
<td>29.8 (9.8)</td>
<td>29.8 (10.3)</td>
<td>29.7 (9.4)</td>
</tr>
<tr>
<td>FEV₁/VC (%)</td>
<td>42.9 (12.9)</td>
<td>40.8 (12.1)</td>
<td>45.1 (13.4)</td>
</tr>
<tr>
<td>Haematocrit (%)</td>
<td>47.2 (5.5)</td>
<td>46.4 (5.3)</td>
<td>47.9 (5.7)</td>
</tr>
<tr>
<td>Observation time (months)</td>
<td>40.9 (19.9)</td>
<td>38.9 (19.7)</td>
<td>42.8 (20.1)</td>
</tr>
<tr>
<td>Steroids. (no. of pts)</td>
<td>39</td>
<td>20</td>
<td>19</td>
</tr>
<tr>
<td>O₂ use (hours)</td>
<td>13.5 (4.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BMI = body mass index; PaO₂ = arterial partial oxygen tension; PaCO₂ = arterial partial carbon dioxide tension; VC = vital capacity; FEV₁ = forced expiratory volume in one second.

*p<0.05 control versus LTOT group.

Results

The treatment group consisted of 103 men and 32 women of mean age 61.2 years (range 40–79). On average the patients were observed for 40.9 months (range 2–85). Mean values of body mass index (BMI), spirometric values, blood gas tensions, and haematocrit at entry to the study were shown in table 1. All patients suffered from severe airflow limitation with mean (SD) forced expiratory volume in one second (FEV₁) 0.83 (0.28).

The control and treatment groups were well matched in all measured variables. The only significant difference at entry to the study was the value of PaO₂ (table 1). To check for the influence of PaO₂ on survival the Cox’s regression coefficients corresponding to the independent variable PaO₂ were calculated separately for each group and provided no evidence that the PaO₂ value influenced the survival of the patients in the study.

In the group receiving LTOT the PaO₂ while breathing oxygen was increased in all patients to more than 8.7 kPa (65 mmHg) (mean PaO₂/ O₂ 9.9 (1.1) kPa (74.0 (7.9) mmHg)). Only in seven patients (three of whom were survivors) was the PaO₂ increased by less than 1 kPa while breathing oxygen. The mean time spent breathing oxygen, calculated from the oxygen concentrator meter readings, was 13.5 (4.4) hours/day.

Seventy patients died during the observation period, 32 in the control group and 38 in the LTOT group. The causes of death are presented in table 2. Most of the deaths in both groups were due to progression of the COPD.

The cumulative survival rate of the total group in the first year was 88%, in the second year 77%, and in the third year 66%. Survival
Figure 2 shows the cumulative survival curves of our patients (in the LTOT and control groups) superimposed on the survival curves of the MRC and NOTT studies. The survival of our patients with COPD with moderate hypoxaemia in both the control and treatment groups was better than that of those with severe hypoxaemia in the MRC and NOTT studies; however, there is a considerable overlap.

The differences in the studied variables between survivors and non-survivors in the total group are presented in table 3. Patients who survived were significantly younger (59.4 vs 62.9 years, \( p = 0.02 \)), had better lung function (VC 2.01 l vs 1.85 l, \( p = 0.038 \) and FEV1 0.89 l vs 0.78 l, \( p < 0.001 \)), and higher BMI (25.1 kg/m\(^2\) vs 22.5 kg/m\(^2\), \( p < 0.001 \)) than non-survivors. The differences in the studied variables between survivors and non-survivors in the control and treatment groups separately are presented in table 4. In the oxygen treated group better lung function (VC 2.12 l in survivors vs 1.80 l in non-survivors (\( p = 0.037 \)) and FEV1 0.96 l vs 0.77 l, respectively (\( p = 0.004 \)) and higher BMI (25.6 vs 22.6 kg/m\(^2\), \( p = 0.017 \)) predicted better survival. In the control group patients who survived were significantly younger (60.8 vs 64.2 years, \( p < 0.05 \)) and had higher BMI (24.6 vs 22.5 kg/m\(^2\), \( p < 0.05 \)) than those who died.

Interestingly, survivors in the treatment group breathed oxygen for a shorter time (12.7 hours/day) than non-survivors (14.2 hours/day), although the difference was not statistically significant. We have found no differences in survival in patients using oxygen for 15 or more hours/day compared with those less compliant (\( p = 0.376 \)). When oxygen use was stratified there were 10 survivors and 11 non-survivors who breathed oxygen for less than 12 hours, 11 patients in each group who used oxygen for 12–15 hours, and only nine survivors compared with 16 non-survivors who breathed oxygen for more than 15 hours/day.

The mean Pao\(_2\) in our patients was 8.0 kPa (60.4 mmHg) with 74 patients having a Pao\(_2\) of \( \leq 8.0 \) kPa and 61 patients with a Pao\(_2\) of \( >8.0 \) kPa. No differences in survival were found in these subgroups of patients (fig 3). We also found that, among the LTOT group who sur-

---

### Table 3: Mean (SD) Differences in Studied Variables in Survivors versus Non-survivors in the Total Study Group

<table>
<thead>
<tr>
<th>Variable</th>
<th>Survivors (n=65)</th>
<th>Non-survivors (n=70)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59.4 (8.3)</td>
<td>62.9 (8.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>M/F</td>
<td>26/9</td>
<td>26/6</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>25.1 (4.9)</td>
<td>22.5 (4.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pao(_2) (kPa/mmHg)</td>
<td>8.1 (0.4)/60.5 (2.9)</td>
<td>8.1 (0.4)/60.4 (2.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Paco(_2) (kPa/mmHg)</td>
<td>5.9 (0.4)/44.5 (6.8)</td>
<td>5.8 (0.0)/43.6 (6.7)</td>
<td>NS</td>
</tr>
<tr>
<td>VC (%)</td>
<td>51.0 (11.8)</td>
<td>47.0 (11.8)</td>
<td>NS</td>
</tr>
<tr>
<td>VC (%) pred</td>
<td>51.0 (11.8)</td>
<td>47.0 (11.8)</td>
<td>NS</td>
</tr>
<tr>
<td>FEV1 (%)</td>
<td>51.7 (12.8)</td>
<td>48.1 (10.1)</td>
<td>NS</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>0.89 (0.30)</td>
<td>0.78 (0.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1/VC (%)</td>
<td>41.7 (13.5)</td>
<td>39.9 (10.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Haematocrit (%)</td>
<td>47.9 (6.5)</td>
<td>46.5 (4.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Observation time (months)</td>
<td>52.0 (12.9)</td>
<td>30.5 (19.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Steroids (no. of pts)</td>
<td>13</td>
<td>26</td>
<td>NS</td>
</tr>
</tbody>
</table>

Table 4: Comparison of Mean (SD) Studied Variables in Survivors versus Non-survivors in the Control and LTOT Groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Controls (n=35)</th>
<th>LTOT (n=36)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.8 (7.3)</td>
<td>64.2 (8.8)‡</td>
<td></td>
</tr>
<tr>
<td>M/F</td>
<td>26/9</td>
<td>24/6</td>
<td></td>
</tr>
<tr>
<td>Pao(_2) (kPa/mmHg)</td>
<td>7.9 (0.4)/59.2 (2.9)</td>
<td>7.9 (0.3)/59.5 (2.6)‡</td>
<td></td>
</tr>
<tr>
<td>Paco(_2) (kPa/mmHg)</td>
<td>6.2 (0.9)/46.2 (6.7)</td>
<td>5.9 (0.9)/44.6 (6.6)‡</td>
<td></td>
</tr>
<tr>
<td>VC (%)</td>
<td>51.7 (12.8)</td>
<td>48.1 (10.1)</td>
<td></td>
</tr>
<tr>
<td>VC (%) pred</td>
<td>51.7 (12.8)</td>
<td>48.1 (10.1)</td>
<td></td>
</tr>
<tr>
<td>FEV1 (%)</td>
<td>51.7 (12.8)</td>
<td>48.1 (10.1)</td>
<td></td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>0.89 (0.30)</td>
<td>0.78 (0.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1/VC (%)</td>
<td>41.7 (13.5)</td>
<td>39.9 (10.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Observation time (months)</td>
<td>49.6 (12.8)</td>
<td>27.2 (19.4)‡</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>24.6 (4.6)</td>
<td>22.5 (4.1)‡</td>
<td></td>
</tr>
<tr>
<td>Steroids (no. of pts)</td>
<td>9</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Pao(_2)/Paco(_2) (kPa/mmHg)</td>
<td>9.9 (1.3)/74.5 (9.8)</td>
<td>9.8 (0.9)/73.7 (6.4)</td>
<td></td>
</tr>
</tbody>
</table>

\( * p<0.05; ** p<0.01; *** p<0.001 \) survivors vs non-survivors in LTOT group.
\( ‡ p<0.05 \) between non-survivors in both groups.
\( § p<0.05 \) compared with controls.

---

The analysis using Cox’s regression model showed no differences in survival between oxygen treated and control groups (fig 1). The hazard ratio to be a member of the control group is equal to 0.916 with a 95% confidence interval of 0.571 to 1.471 (the value 1, representing an equal hazard for LTOT and control groups, is well covered by this interval). Additional analysis using the Gehan-Wilcoxon statistic with the value of -0.018 (\( p = 0.49 \)) confirmed the lack of difference between the control and treatment groups.
Effect of LTOT on survival in patients with COPD

Survival time (months)
Cumulative survival rate
1.0
0.8
0.6
0.4
0.2
0.0
24 48 72 84 96

BMI <20 kg/m²
BMI >25 kg/m²
BMI 20–25 kg/m²

Survival time (months)
Cumulative survival rate
1.0
0.8
0.6
0.4
0.2
0.0
24 48 72 84 96

PaO₂ < 8.0 kPa
PaO₂ > 8.0 kPa

Figure 3 Cumulative survival rate in the total group stratified for arterial oxygen tension (PaO₂). No difference in survival was found in patients with PaO₂ ≤ 8.0 kPa and PaO₂ > 8.0 kPa (p = 0.906).

Figure 5 Cumulative survival rate in the total group stratified for body mass index (BMI). Patients with BMI > 25 kg/m² survived significantly longer than those with BMI < 20 kg/m² (p = 0.005).

Discussion
The prescription of LTOT to patients with COPD with moderate hypoxaemia did not prolong life. Moreover, within the oxygen treated group survival was found between oxygen use and survival.

The beneficial effect of LTOT in preventing the progression of pulmonary hypertension is well known, but this treatment does not influence the progression of the airflow limitation. To date only two controlled studies have been reported on the effects of long term oxygen breathing in patients with COPD with advanced respiratory failure – the MRC and NOTT studies – both of which found that breathing oxygen for more than 15 hours/day substantially prolonged survival. The longer the oxygen breathing time the better survival was observed.

Although the upper limit of PaO₂ for inclusion in these studies was set at 8 kPa (60 mmHg), most of the patients had a PaO₂ of less than 7.3 kPa (55 mmHg). In the MRC study the mean PaO₂ on air was only 6.7 kPa (50.4 mmHg) for the treated group and 6.9 kPa (51.5 mmHg) for the controls, whereas in the NOTT study it was 6.8 kPa (50.8 mmHg) for the continuous therapy group and 6.9 kPa
(51.5 mmHg) for the nocturnal oxygen group. Mean \(P_{aO_2}\) in our patients was much higher (8.0 kPa (60.4 mmHg)). Although it might have been anticipated, no differences in survival were found in subgroups of patients with \(P_{aO_2} \leq 8\) kPa and >8.0 kPa at entry to the study.

Our treated and control groups were well matched at the beginning of the study. The only statistically significant difference (although clinically trivial) between the groups was in \(P_{aO_2}\), which was lower in the LTOT group. This difference was probably due to a narrow range (only 1.3 kPa (10 mmHg)) of inclusion \(P_{aO_2}\) values. Such a range restricted the standard deviation, thereby increasing the significance of small differences in mean values. Moreover, the \(P_{aO_2}\) did not influence the survival in either group or the study group as a whole, which is the best evidence that the baseline differences were not important.

In the two landmark studies survival was positively associated with the number of hours of oxygen breathing. In our study compliance with the treatment was similar to that of the MRC trial. However, we observed no differences between oxygen use in survivors (12.7 hours/day) and non-survivors (14.2 hours/day). When we analysed a subgroup of patients who breathed oxygen for more than 15 hours/day there were more non-survivors than survivors in that group. This finding may be explained by the fact that surviving patients were younger, had better lung function, and did not feel the need to comply with the prescribed treatment (17 hours and more). Similarly, in a study by the ANTADIR group 65% of patients with \(P_{aO_2} >8.0\) kPa (60 mmHg) decreased their daily oxygen use to below 15 hours because they found the longer treatment not necessary.\(^{18}\)

From two recent studies from Sweden\(^4\) and the ANTADIR group in France\(^2\) it appears that survival in patients with a higher prescription of oxygen is inferior to that in patients with a lower oxygen prescription and may reflect the physician’s perception of the severity of the disease.

Survival in our group was similar to that of patients in the IPPB trial with a similar degree of airflow limitation and no hypoxaemia.\(^{21}\) Survival in both the treatment and control groups was better than survival of the patients in the MRC trial\(^1\) with more advanced airflow limitation (FEV\(_1\), 0.76 l in oxygen treated group, 0.63 l in controls) and more severe hypoxaemia. It was also better than the survival of the nocturnal oxygen therapy group and similar to the survival in the continuous oxygen treatment group in the NOTT trial.\(^2\) In a comparison of patients in the IPPB trial without hypoxaemia with NOTT patients with the same degree of airflow limitation, Athonisen has found that the correction of hypoxaemia improved the survival rates of the continuous oxygen therapy group to the rate of survival of patients with no blood gas disturbances, as opposed to the less favourable survival of the nocturnal oxygen group.\(^2\) The correction of hypoxaemia in the MRC trial also improved the survival in oxygen treated patients compared with controls.\(^1\) Oxygen treatment was of benefit to the patients such as those in the MRC and NOTT studies, but not to our patients. There was, however, a considerable overlap in the survival of our patients and those from the abovementioned studies.

Patients receiving LTOT increased their \(P_{aO_2}\) on average by 2 kPa while breathing oxygen. Almost all improved their oxygenation by at least 1 kPa, which is in accordance with the UK guidelines for prescribing oxygen.\(^2\) An equal number of non-responders was found among the survivors and non-survivors, suggesting that this factor did not influence the survival.

This comparison of our data with that in the literature clearly confirms that survival in patients with COPD is influenced by airflow limitation and that LTOT prolongs life only when severe hypoxaemia ensues.

In our patients survival depended on lung function and age at entry to the study. Patients who survived had better preserved lung function and were significantly younger. In many previous studies the age has also proved to be a significant predictor of survival.\(^{42,12,22}\)

In a number of studies of patients with COPD\(^{27,28}\) survival was influenced by the body mass. Undernourished patients did not do so well as those who were overweight\(^2\) and this effect was independent of the lung function.\(^{26}\) Also, our patients who survived had a significantly higher BMI than those who did not survive and the survival rate improved with increasing body mass independently of FEV\(_1\), as well as after adjusting BMI for FEV\(_1\), similar to the results of the IPPB trial.\(^2\)

We have found that, after mutually adjusting BMI and FEV\(_1\), only BMI proved to have a significant influence on survival. This may be explained by the extremely narrow range of very low FEV\(_1\) values. However, FEV\(_1\) proved to be significantly lower in non-survivors and the value of 0.8 l resulted in significant differences in survival in those with less and more advanced airflow limitation.

Another factor that should be taken into account in studying survival is stopping smoking. It is well known that quitting smoking slows the decline in FEV\(_1\),\(^{27,26}\) and improves the survival, although such an influence becomes apparent only after approximately six years of follow up.\(^{18}\) All our patients declared to be non-smokers when starting LTOT, however seven had resumed smoking as judged by raised carboxyhaemoglobin level at 1–3 months after entering the study. All these patients survived. The carboxyhaemoglobin level was not checked in the control group. It is extremely difficult to draw any conclusion from this finding due to the limited number of patients in whom we could study these influences.

It has been suggested that use of long term corticosteroids in women with COPD may adversely affect survival.\(^10\) Such treatment was prescribed in 29% of our patients and twice as many patients receiving steroids died as survived. However, this difference did not reach statistical significance. As we included only patients with COPD with fixed airway ob-
Effect of LTOT on survival in patients with COPD

The effect of LTOT on survival in patients with COPD

We conclude that, in patients with COPD with chronic airflow limitation but moderate hypoxaemia, there is no difference in survival rates between patients treated and not treated with domiciliary oxygen. In addition, oxygen use for longer periods did not improve the survival rate. These results suggest that prescription of LTOT in this specific group of patients with COPD should be done more cautiously, reserving this expensive treatment for patients with severe hypoxaemia as in the UK guidelines.23

The authors wish to thank the following physicians from the regional LTOT centres for their participation in the study: M Czajkowska-Malinowska (Bydgoszcz), A Kubica (Bystrzyca), J Dobrozińska (Chelm), G Stasiakiewicz (Ciechanów), M Filipowicka and L Sołowska (Kراكów), E Sorna (Łódź), T Izhicka (Suwałki), M J Palka (Wrocław).


